Cargando…

Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?

The first clinical trials of the safety and efficacy of interferon-alpha2 (IFN-alpha2) were performed about 30 years ago. Since then, several single-arm studies have convincingly demonstrated that IFN-alpha2 is a highly potent anti-cancer agent in several cancer types but unfortunately not being exp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hasselbalch, Hans Carl, Holmström, Morten Orebo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323070/ https://www.ncbi.nlm.nih.gov/pubmed/30203226 http://dx.doi.org/10.1007/s00281-018-0700-2

Ejemplares similares

Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms
por: Holmström, Morten Orebo, et al.
Publicado: (2020)

Recombinant Interferon-β in the Treatment of Polycythemia Vera and Related Neoplasms: Rationales and Perspectives
por: Hasselbalch, Hans, et al.
Publicado: (2022)

Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms
por: Skov, Vibe, et al.
Publicado: (2022)

New Perspectives of Interferon-alpha2 and Inflammation in Treating Philadelphia-negative Chronic Myeloproliferative Neoplasms
por: Hasselbalch, Hans C., et al.
Publicado: (2021)

Data‐driven analysis of JAK2V617F kinetics during interferon‐alpha2 treatment of patients with polycythemia vera and related neoplasms
por: Pedersen, Rasmus K., et al.
Publicado: (2020)

Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment
por: Kjær, Lasse, et al.
Publicado: (2016)

Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia
por: Agarwal, M. B., et al.
Publicado: (2015)

Therapeutic cancer vaccination against mutant calreticulin in myeloproliferative neoplasms induces expansion of specific T cells in the periphery but specific T cells fail to enrich in the bone marrow
por: Holmström, Morten Orebo, et al.
Publicado: (2023)

Safety and efficacy of combination therapy of interferon‐α2 and ruxolitinib in polycythemia vera and myelofibrosis
por: Mikkelsen, Stine Ulrik, et al.
Publicado: (2018)

Myeloproliferative neoplasms in five multiple sclerosis patients()
por: Thorsteinsdottir, Sigrun, et al.
Publicado: (2013)

Ocular Manifestations in Patients with Philadelphia-Negative Myeloproliferative Neoplasms
por: Liisborg, Charlotte, et al.
Publicado: (2020)

An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial
por: Grauslund, Jacob Handlos, et al.
Publicado: (2023)

Patients With Myeloproliferative Neoplasms Harbor High Frequencies of CD8 T Cell-Platelet Aggregates Associated With T Cell Suppression
por: Carnaz Simões, Ana Micaela, et al.
Publicado: (2022)

The clinical role of interferon alpha in Philadelphia-negative myeloproliferative neoplasms
por: Yoon, Seug Yun, et al.
Publicado: (2021)

Interferon alpha therapy in essential thrombocythemia and polycythemia vera - a systematic review and meta-analysis
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2020)

Pegylated Interferon Alpha-2b in Patients With Polycythemia Vera and Essential Thrombocythemia in the Real World
por: Sun, Yingxin, et al.
Publicado: (2021)

A remarkable hematological and molecular response pattern in a patient with polycythemia vera during combination therapy with simvastatin and alendronate
por: Sørensen, Anders Lindholm, et al.
Publicado: (2016)

Corrigendum: Patients with myeloproliferative neoplasms harbor high frequencies of CD8 T cell-platelet aggregates associated with T cell suppression
por: Simões, Ana Micaela Carnaz, et al.
Publicado: (2022)

Can pegylated interferon improve the outcome of polycythemia vera patients?
por: Crisà, Elena, et al.
Publicado: (2017)

Mediators of Inflammation in Myeloproliferative Neoplasms: State of the Art
por: Hermouet, Sylvie, et al.
Publicado: (2015)

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) arising in the setting of polycythemia vera (PV): An illustration of the emerging role of flow cytometry analysis in monitoring progression of myeloproliferative neoplasms
por: El Hussein, Siba, et al.
Publicado: (2022)

Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study
por: Sørensen, Anders Lindholm, et al.
Publicado: (2020)

Straightforward Identification of Masked Polycythemia Vera Based on Proposed Revision of World Health Organization Diagnostic Criteria for BCR-ABL1-Negative Myeloproliferative Neoplasms
por: Chu, Daehyun, et al.
Publicado: (2015)

Vascular Diseases In Patients With Chronic Myeloproliferative Neoplasms – Impact Of Comorbidity
por: Frederiksen, Henrik, et al.
Publicado: (2019)

Revisiting Circulating Extracellular Matrix Fragments as Disease Markers in Myelofibrosis and Related Neoplasms
por: Hasselbalch, Hans Carl, et al.
Publicado: (2023)

Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b
por: Them, Nicole CC, et al.
Publicado: (2015)

Interferon-Alpha 2-a and Its Dual Effect in Treating Two Diseases (Hepatitis C and Polycythemia Vera)
por: Shwaylia, Hawraa, et al.
Publicado: (2021)

Interferon Alpha Therapy Increases Pro-Thrombotic Biomarkers in Patients with Myeloproliferative Neoplasms
por: Faille, Dorothée, et al.
Publicado: (2020)

Minimal change disease caused by polycythemia vera: A case report
por: Xu, Li, et al.
Publicado: (2022)

The gut microbiota in patients with polycythemia vera is distinct from that of healthy controls and varies by treatment
por: Eickhardt-Dalbøge, Christina Schjellerup, et al.
Publicado: (2022)

Ruxolitinib in Myelofibrosis and Polycythemia Vera
por: Wolfe, Leah
Publicado: (2016)

Thromboembolic events in polycythemia vera
por: Griesshammer, Martin, et al.
Publicado: (2019)

Genetic Background of Polycythemia Vera
por: Regimbeau, Mathilde, et al.
Publicado: (2022)

Monitoring Minimal Residual Disease in the Myeloproliferative Neoplasms: Current Applications and Emerging Approaches
por: Haslam, Karl, et al.
Publicado: (2016)

Differential cytokine network profile in polycythemia vera and secondary polycythemia
por: Cacemiro, Maira da Costa, et al.
Publicado: (2020)

Jak2V617F myeloproliferative neoplasm stem cells and interferon-alpha
por: Lane, Steven W., et al.
Publicado: (2013)

Lemierre’s Syndrome in an Elderly Female Patient with Polycythemia Vera: Does Polycythemia Vera Predispose to Lemierre’s Syndrome?
por: Kundal, Sanchit V., et al.
Publicado: (2021)

Patients with myeloproliferative neoplasms and high levels of systemic inflammation develop age-related macular degeneration
por: Liisborg, Charlotte, et al.
Publicado: (2020)

Polycythemia vera presenting with bilateral papilledema
por: Nithyanandam, Suneetha
Publicado: (2009)

Electrocardiographic Findings in Patients with Polycythemia Vera
por: Kayrak, Mehmet, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_5s0s1te84ncvc0la6f5mrigkf5